RD
RDHL.US Redhill Biopharma Ltd
- Market cap
- USD 3.20M
- P/E
- -
- P/B
- 1.01x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is RDHL.US undervalued?
Graham numberThe Graham number of Redhill Biopharma Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Redhill Biopharma Ltd fundamental analysis
No fundamental analysis for Redhill Biopharma Ltd yet.
Redhill Biopharma Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prosta…
Full company profileRedhill Biopharma Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Redhill Biopharma Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 101K | 4.01M | 8.36M | 6.29M | 64.4M | 85.8M | 61.8M | 6.53M | 8.04M | 286K | - |
| Gross Profit | -30.4M | 1.88M | 5.52M | 4.03M | 27.5M | 36.4M | 28.5M | 3.07M | 4.85M | 286K | - |
| Operating Income | -30.5M | -52.0M | -39.3M | -43.2M | -63.7M | -81.1M | -42.8M | 12.6M | -14.6M | -7.91M | -16.5M |
| EBITDA | -30.5M | -45.5M | -38.7M | -40.7M | -55.0M | -63.0M | -22.2M | 26.3M | -7.59M | -7.65M | -15.9M |
| Net Income | -29.4M | -45.5M | -38.8M | -42.3M | -76.2M | -97.7M | -71.7M | 23.9M | -8.27M | -429K | -24.4M |
| EPS | -1,140 | -1,290 | -840 | -712 | -1,046 | -1,050 | -579 | 46 | -3.35 | -0.14 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 74.2M | 57.3M | 62.4M | 74.1M | 180M | 181M | 159M | 23.0M | 18.0M | 25.3M | 26.3M |
| Total Liabilities | 11.5M | 12.3M | 11.2M | 14.1M | 166M | 172M | 207M | 21.0M | 22.7M | 21.1M | 27.4M |
| Shareholders' Equity | 62.7M | 45.1M | 51.2M | 60.0M | 13.9M | 8.88M | -48.4M | 2.07M | -4.68M | 4.27M | -1.08M |
| Cash & Short-term Investments | 66.2M | 46.2M | 53.2M | 47.9M | 29.8M | 38.0M | 20.0M | 6.36M | 4.62M | 3.97M | 5.16M |
| Total Debt | - | - | - | 3.82M | 86.9M | 87.8M | 123M | 1.17M | 356K | 1.07M | 1.08M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -28.3M | -44.8M | -34.5M | -40.7M | -48.6M | -65.0M | -29.2M | -35.8M | -9.37M | -9.65M | -18.2M |
| Capital Expenditure | 120K | 1.18M | 58.0K | 203K | 53.8M | 115K | 198K | 11.0K | 9.00K | 5.00K | 56.0K |
| Free Cash Flow | -28.4M | -46.0M | -34.5M | -41.0M | -102M | -65.2M | -29.4M | -35.8M | -9.38M | -9.66M | -18.3M |
| Ratios | |||||||||||
| ROE | -46.8% | -101.1% | -75.8% | -70.5% | -549.4% | -1,101.3% | - | 1,155.9% | - | -10.1% | - |
| ROA | -39.6% | -79.4% | -62.2% | -57.1% | -42.3% | -53.9% | -45.1% | 103.8% | -45.8% | -1.7% | -92.9% |
| Net Profit Margin | -29,079.2% | -1,136.6% | -464.4% | -672.5% | -118.4% | -114.0% | -116.0% | 366.2% | -102.8% | -150.0% | - |
| Debt to Equity | - | - | - | 0.06x | 6.27x | 9.89x | - | 0.57x | - | 0.25x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Redhill Biopharma Ltd dividends
Redhill Biopharma Ltd has not paid dividends in the last 9 fiscal years.
Last stock split: 1:25 on Aug 20, 2024.
Who owns Redhill Biopharma Ltd
- Insiders 0.00%
- Institutions 4.56%
- Public & others 95.44%
- Shares outstanding 8.89M
- Free float 4.20M
Top funds holding RDHL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Yorkville Health Care Opportunities Cl F | 14.00 | 0.00% | 0.00% | Feb 2025 |
Top institutions holding RDHL.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Yorkville Advisors Global, LP | 122K | 1.37% | -65.19% | Jun 2026 |
| Gagnon Securities LLC | 88.4K | 0.99% | 0.00% | Sep 2026 |
| Citadel Advisors Llc | 65.3K | 0.74% | +215.97% | Jun 2026 |
| Rhumbline Advisers | 12.2K | 0.14% | -11.61% | Sep 2026 |
| Lido Advisors, LLC | 11.0K | 0.12% | 0.00% | Jun 2026 |
| GAMMA Investing LLC | 6.96K | 0.08% | +4.08% | Jun 2026 |
| Citigroup Inc | 4.38K | 0.05% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 3.39K | 0.04% | 0.00% | Jun 2026 |
| Royal Bank of Canada | 351.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 100.00 | 0.00% | -87.89% | Jun 2026 |
| Mercer Global Advisors Inc. | 50.00 | 0.00% | 0.00% | Jun 2026 |
| SBI Securities Co Ltd | 15.00 | 0.00% | +275.00% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.00 | 0.00% | 0.00% | Jun 2026 |
| StoneX Group Inc | 0.00 | 0.00% | -100.00% | Jun 2026 |
| XTX Topco Ltd | 0.00 | 0.00% | -100.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Your Advocates Ltd., LLP | 0.00 | 0.00% | -100.00% | Jun 2026 |
Redhill Biopharma Ltd company profile
- Company name
- Redhill Biopharma Ltd
- Ticker
- RDHL.US
- Exchange
- USA Stocks
- Listed since
- Jan 7, 2013
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 13
- Fiscal year end
- December
- Address
- 21 Ha?arba?a Street, Tel Aviv-Yafo, Israel, 6473921
- Phone
- 972 3 541 3131
- Website
- redhillbio.com
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for treating patients hospitalized with SARS-CoV-2 severe COVID-19 pneumonia, prostate cancer, nuclear radiation protection; and host directed anti-viral; Rebyota, a microbiota-based therapy for prevention of recurrent Clostridioides difficile infection; RHB-107 (upamostat) for treating outpatients infected with SARS-CoV-2 (COVID-19 disease) and advanced unresectable cholangiocarcinoma; RHB-104 for Crohn's disease; RHB-102 (Bekinda) for the treatment of acute gastroenteritis and gastritis, irritable bowel syndrome with diarrhea, and oncology support anti-emetic; and RHB-204 that is in Phase 3 clinical trial for the treatment of pulmonary Mycobacterium avium complex disease in adults. It also commercializes Clenpiq, a ready-to-drink low-volume bowel preparation. The company was incorporated in 2009 and is headquartered in Tel Aviv-Yafo, Israel.
Redhill Biopharma Ltd management
10- Mr. Dror Ben-AsherCo-Founder, Chairman & CEO · born 1966
- Mr. Razi IngberChief Financial Officer · born 1984
- Mr. Gilead Raday MPhil, MScChief Operating Officer · born 1975
- Mr. Adi FrishChief Corporate & Business Development Officer · born 1970
- Mr. Rick D. ScruggsChief Commercial Officer & Director · born 1960
- Dr. Mark L. Levitt M.D., Ph.D.Chief Scientific Officer
- Ms. Alexandra OkmianSenior Business Development & Investor Relations Manager
- Dr. Reza Fathi Ph.D.Senior Vice President of Research & Development · born 1955
- Mr. Guy Goldberg J.D.Chief Business Officer · born 1976
- Ms. Patricia Anderson B.Sc. RACSenior Vice President of Regulatory Affairs